Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Efficacy and safety results from the ANCHOR trial

Enrique Ocio • 29 Sep 2023
IMS 2023
Multiple Myeloma Bortezomib Daratumumab Dexamethasone Melflufen
ANCHOR

Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, shares efficacy and safety results from the ANCHOR trial (NCT03481556), which is evaluating the use of melflufen plus dexamethasone and either daratumumab or bortezomib to treat patients with relapsed/refractory (R/R) multiple myeloma. Dr Ocio highlights the overall response rate (ORR), the progression-free survival (PFS), and the adverse events observed in both treatment arms. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Enrique Ocio

2:03
The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM
Enrique Ocio • 29 Sep 2023
1:27
Clonal hematopoiesis in multiple myeloma and implications for therapy
Enrique Ocio • 29 Sep 2023
Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023
Novel therapeutic strategies in multiple myeloma
Carlos Fernández De Larrea et al. • 15 Apr 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals